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OBJECTIVES This study was designed to determine if non-aspirin non-steroidal anti-inflammatory drugs
(NANSAIDs) are associated with lower odds of myocardial infarction (MI) and if
NANSAIDs, particularly ibuprofen, interfere with aspirin’s cardioprotective effect.
BACKGROUND The NANSAIDs may reduce the risk of MI but may also interfere with aspirin’s
cardioprotective effect.
METHODS A case-control study was conducted, with cases of first, nonfatal MI identified prospectively
and controls identified randomly from the community.
RESULTS The use of NANSAIDs was associated with a significant reduction in MI among those not
using aspirin (adjusted odds ratio [OR] 0.53; 95% confidence interval [CI]: 0.42 to 0.67).
This was true for both ibuprofen (adjusted OR 0.52; 95% CI: 0.39 to 0.69) and naproxen
(adjusted OR 0.48; 95% CI: 0.28 to 0.82). Although aspirin itself was associated with
decreased odds of MI in those not also using NANSAIDs (adjusted OR relative to no aspirin
use 0.79; 95% CI: 0.63 to 0.98), it was not associated with decreased odds of MI among those
who were using NANSAIDs (OR 1.28; 95% CI: 0.85 to 1.94; p value for interaction 
0.026). The association of aspirin and reduced odds of MI diminished with increasing
frequency of NANSAID use (test for interaction p  0.006), particularly for ibuprofen (p 
0.018). Among frequent (4 times/week) NANSAID users, the OR for aspirin versus no
aspirin was 2.04 (95% CI: 1.06 to 3.94). Users of prophylactic aspirin plus frequent ibuprofen
had an OR relative to aspirin-only users of 2.03 (95% CI: 0.60 to 6.84).
CONCLUSIONS In the absence of aspirin use, NANSAIDs are associated with reduced odds of MI. In those
using aspirin, NANSAIDs do not provide additional protection. Additional study is needed
to determine the clinical impact of using NANSAIDs along with aspirin for
cardioprotection. (J Am Coll Cardiol 2004;43:985–90) © 2004 by the American College of
Cardiology Foundationp
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bt has been estimated that more than 70 million prescrip-
ions and 30 billion over-the-counter tablets of non-aspirin
on-steroidal anti-inflammatory drugs (NANSAIDs) are
See page 991
old annually in the U.S. alone and that 13 million Amer-
cans use NANSAIDs on a regular basis (1). Although they
re effective analgesics and anti-inflammatories, they may
lso have an effect on myocardial infarction (MI) risk.
From the *Center for Clinical Epidemiology and Biostatistics and Department of
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hiladelphia, Pennsylvania; and the †Cardiovascular Division, Department of Med-
cine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Sup-
orted by a grant from the National Institutes of Health. A supplement for research
till ongoing was provided by Searle Pharmaceuticals Inc. (now Pharmacia). Dr.
trom has served as a consultant for Pfizer (associated with Pharmacia) and for most
ther pharmaceutical manufacturers who make either nonselective NANSAIDs or
OX-2 inhibitors. Dr. Kimmel has also served as a consultant to the manufacturers
f nonselective NANSAIDs, all unrelated to NANSAIDs. Dr. Kimmel currently
eceives grant support from Merck for research on COX-2 inhibitors. Dr. Reilly has
rant support from Merck, including for one study of NANSAIDs and COX-2
nhibitors.
Manuscript received April 16, 2003; revised manuscript received August 11, 2003,
tccepted August 19, 2003.Nonselective NANSAIDs (those that inhibit both the
latelet cyclooxygenase enzyme responsible for thrombox-
ne A2 formation and subsequent platelet aggregation)
yclooxygenase (COX)-1, and the COX-2 enzyme (2) may
educe the risk of MI in the absence of aspirin use.
ecisions regarding the choice of drugs for analgesia and
nflammation currently are influenced by the need to min-
mize bleeding risk without consideration of possible ben-
fits of MI protection (1). Although several studies have
uggested a protective effect of NANSAIDs, particularly
aproxen (3–5), on MI, others have not (6,7). However,
hese studies used electronic prescription records, so they
ould not measure the fairly common use of over-the-
ounter NANSAIDs or aspirin (8) and, therefore, could not
rovide definitive conclusions. Relatedly, a trial comparing
he COX-2 inhibitor rofecoxib with the NANSAID
aproxen found a higher rate of MI among the COX-2
sers (9). This could be due to an increased risk from the
OX-2 inhibitor, decreased risk from the NANSAID, or
oth.
The NANSAIDs, particularly ibuprofen, could also in-erfere with the clinical benefit of aspirin in reducing MI
r
(
m
t
p
r
t
f
M
S
a
P
a
M
M
M
s
c
t
v
a
i
6
h
d
t
D
l
t
h
a
i
r
m
e
a
p
c
i
n
a
m
i
D
w
t
c
A
p
a
c
s
r
e
o
i
n
c
h
d
w
u
u
F
N
p
a
c
m
a
(
a
s
a
b
t
m
c
a
o
t
r
b
a
i
c
m
b
i
N
c
a
c
g
986 Kimmel et al. JACC Vol. 43, No. 6, 2004
Non-Steroidals and MI March 17, 2004:985–90isk. Pharmacologic data have demonstrated this interaction
10), but the clinical consequences are unknown.
We conducted a case-control study specifically to deter-
ine the effects of nonselective NANSAIDs on MI risk and
he interaction between NANSAIDs and aspirin. We hy-
othesized that nonselective NANSAIDs would reduce the
isk of first, nonfatal MI in the absence of aspirin use, but
hat NANSAIDs, particularly ibuprofen, could also inter-
ere with the cardioprotective effect of aspirin.
ETHODS
tudy site and participants. The study was conducted
mong 36 hospitals in a five-county region surrounding
hiladelphia. Cases were subjects between the ages of 40
nd 75 years with a first, nonfatal MI, hospitalized from
ay 1998 through April 2001 and identified prospectively.
yocardial infarction was validated using criteria from the
innesota Heart Survey (11). Of the 1,151 cases, 677 had
ufficient data to validate MI. Of these, 581 (86%) met the
riteria for MI; the remaining 96 were excluded. Excluding
he 191 cases that did not have complete information to
erify MI and the 283 for whom medical records were not
vailable did not change the study results, so they are
ncluded. The participation rate among eligible cases was
0%. Approximately four community controls with no
istory of MI were selected for each case using random digit
ialing. The participation rate among known eligible con-
rols was 54%.
ata collection. Exposure and covariate data were col-
ected for all cases and controls using the same structured
elephone interview in identical settings (the participants’
omes). Subjects were not told of the study hypothesis at
ny point during the study.
In order to maximize the validity of NANSAID exposure
nformation, cases were interviewed only if they could be
eached within four months of their MI. To further maxi-
ize recall (12,13), all cases and controls were prompted for
xposure information with indication-specific questions
bout NANSAID use, examination of photographs with
ictures of NANSAID products (including pictures of their
ontainers when available) mailed to them before the
nterview, and reading of all other available NANSAID
ames for which pictures were not available. All participants
lso were asked to have all of the containers for the
edications that they took during the index week (defined
Abbreviations and Acronyms
CI  confidence interval
COX  cyclooxygenase
MI  myocardial infarction
NANSAID  non-aspirin non-steroidal
anti-inflammatory drug
OR  odds ration the following text) available during the interview. Tefinition of exposure. The a priori definition of exposure
as any NANSAID or aspirin use within one week before
he index date (the date of first onset of symptoms of MI for
ases and the date of the telephone interview for controls).
nalysis. The primary analysis of the study focused, a
riori, on the association between nonselective NANSAIDs
nd the odds of MI in the absence of aspirin use. We also
ompared the effects of individual NANSAIDs among
ingle NANSAID users relative to non-users. Based on
ecent pharmacological data (10), we also planned, prior to
xamining our data, to analyze the effects of aspirin on the
dds of MI, stratifying by NANSAID use and focusing on
buprofen, the only NANSAID to date known to antago-
ize the antiplatelet effects of aspirin (10). Because of
oncerns of uncontrollable confounding among those with a
istory of coronary artery disease, we adjusted for coronary
isease by exclusion in the aspirin analyses. In these analyses
e considered “frequent users” of NANSAIDs to be those
sing NANSAIDs at least 4 times/week and “infrequent
sers” to be those who used NANSAIDs 4 times/week.
inally, in order to estimate the potential effect of adding an
ANSAID to a regimen of prophylactic aspirin, we com-
ared the effects of NANSAIDs plus aspirin to aspirin use
lone among those who reported using aspirin to prevent
ardiovascular disease.
In order to adjust for possible confounding, we performed
ultiple logistic regression analyses that included, a priori,
ll variables in Table 1. We also tested for confounding
defined as a change in the odds ratio [OR] of 10% with
djustment) for the following: calendar year; alcohol con-
umption; history of renal dysfunction, heart failure, or
rthritis; and use of either beta-blockers, calcium channel
lockers, angiotensin-converting enzyme inhibitors, ni-
rates, cholesterol lowering medications, vitamins, or hor-
one replacement therapy.
In order to estimate the possible effects of recall bias, we
ompared those reporting NANSAID use (without acet-
minophen use) with those reporting use of acetaminophen
nly. We also analyzed the effect of NANSAIDs among
wo groups of subjects most likely to have the most accurate
ecall: cases and controls who had all of their medication
ottles from the index week available during the interview
nd cases who were interviewed within two months of their
ndex date (12). Finally, we reviewed admission records of
ases to determine if NANSAID use documented in the
edical record was recalled in the telephone interview.
In order to estimate the possible effect of nonparticipation
ias, we used the results from two nonparticipation substud-
es. In the first, we compared the chart-documented use of
ANSAIDs among 129 medical records of non-participant
ases with the chart documentation of NANSAID use
mong participant cases. In the second, we interviewed 182
onsecutive non-participant controls and asked about anal-
esic and anti-inflammatory drug use in the prior week.
his was compared with the results from identical questions
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March 17, 2004:985–90 Non-Steroidals and MIsked of participant controls. We then derived an OR for
ANSAIDs and MI, adjusted for nonparticipation (14).
The study was approved by the institutional review
oards of the University of Pennsylvania and all participat-
ng hospitals.
ESULTS
tudy population. The distribution of risk factors by
ANSAID use is shown separately among cases and
ontrols in Table 1.
ssociation between NANSAIDs and MI. Aspirin and
ANSAIDs were used by 27% and 30% of the study
opulation, respectively. Non-prescription NANSAID use
ade up 78% of all NANSAID use.
The use of NANSAIDs in the index week was associated
able 1. Characteristics of Study Participants
C
NANSAID
Use
(n  200)
ctivity score (mean  SD) 7.08  1.38
ge, yrs (mean  SD) 57.01  9.12
MI, kg/m2 (mean  SD) 30.09  6.53
iabetes mellitus, n (%) 33 (16.5%)
amily history of coronary disease, n (%) 124 (62.0%)
emale gender, n (%) 89 (44.5%)
ypercholesterolemia, n (%) 99 (49.5%)
ypertension, n (%) 114 (57.0%)
nsurance
Medicare 36 (18.2%)
Medicaid/Veterans 13 (6.6%)
Private 142 (71.7%)
None 7 (3.5%)
hysician visits/yr (mean  SD) 6.14  7.39
rior angina/coronary disease, n (%) 30 (15.0%)
ace, n (%)
White 141 (71.2%)
Black 56 (28.3%)
Other 1 (0.5%)
moking history, n (%)
Past 75 (37.5%)
Current 72 (36.0%)
ears of school (mean  SD) 13.04  2.73
p  0.05 comparing NANSAID use to no NANSAID use; †p  0.05 for overall
BMI  body mass index; NANSAID  non-aspirin non-steroidal anti-inflamm
able 2. Association of NANSAIDs With MI, Stratified by Asp
Nonaspirin Users
Cases Co
(n  693) (n 
o NANSAID use 567 (81.8%) 2,025
ANSAID use 126 (18.2%) 1,065
spirin Users (n  362) (n 
o NANSAID use 288 (79.6%) 771
ANSAID use 74 (20.4%) 292
Adjusted for age, gender, race, cigarette smoking, insurance, number of physician v
ody mass index, activity score, years of education, and history of diabetes mellitus, hy
nd nonusers  0.026.CI  confidence interval; MI  myocardial infarction; NANSAIDs  non-aspirin nonith a significant reduction in MI odds among those who
id not use aspirin (Table 2) (adjusted OR 0.53; 95%
onfidence interval [CI]: 0.42 to 0.67). Both ibuprofen
adjusted OR 0.52; 95% CI: 0.39 to 0.69) and naproxen
adjusted OR 0.48; 95% CI: 0.28 to 0.82) were associated
ith lower MI odds among non-users of aspirin. Utilization
ates were too low to analyze other NANSAIDs. Among
hose using aspirin, NANSAIDs were not associated with
ower odds of MI (adjusted OR 0.83; 95% CI: 0.58 to 1.17)
Table 2).
ffect of NANSAIDs on the aspirin-MI association.
mong those not using NANSAIDs, aspirin use was
ssociated with a statistically significant reduction in odds of
I, compared with no aspirin use (adjusted OR 0.79; 95%
I: 0.63 to 0.98) (Fig. 1). Among those using NANSAIDs
Control Subjects
No NANSAID
Use
(n  855)
NANSAID
Use
(n  1,357)
No NANSAID
Use
(n  2,796)
6.96  1.31 7.29  1.22 7.31  1.23*
58.07  9.24 51.14  8.64 53.16  9.46*
28.94  5.70* 27.73  6.03 27.15  5.57*
211 (24.7%)* 87 (6.4%) 206 (7.4%)
470 (55.0%) 585 (43.1%) 1,152 (41.2%)
294 (34.4%)* 904 (66.6%) 1,530 (54.7%)*
383 (44.8%) 322 (23.8%) 745 (26.7%)*
460 (53.8%) 387 (28.5%) 839 (30.0%)
141 (17.1%) 95 (7.1%) 252 (9.2%)
29 (3.5%) 23 (1.7%) 52 (1.9%)
624 (75.8%) 1,173 (87.8%) 2,316 (85.0%)
29 (3.5%) 45 (3.4%) 105 (3.9%)
7.52  23.22 4.66  6.26 4.71  9.02*
161 (18.8%) 54 (4.0%) 104 (3.7%)
592 (70.3%) 1,132 (83.7%) 2,218 (79.8%)†
220 (26.1%) 183 (13.5%) 458 (16.5%)
30 (3.6%) 37 (2.7%) 105 (3.8%)
290 (34.3%) 422 (31.2%) 917 (33.0%)
291 (34.4%) 287 (21.2%) 615 (22.1%)
13.10  2.71 14.34  2.44 14.17  2.48*
rison among the group.
rugs.
se
s
Unadjusted OR
(95% CI)
Adjusted OR*
(95% CI)0)
%) Reference Reference
%) 0.42 (0.34–0.52) 0.53 (0.42–0.67)
3)
%) Reference Reference
%) 0.68 (0.51–0.91) 0.83 (0.58–1.17)
the prior year, prior angina or coronary disease, family history of coronary disease,
sion, and hypercholesterolemia. The p value for interaction OR between aspirin usersases
compa
atory dirin U
ntrol
3,09
(65.5
(34.5
1,06
(72.5
(27.5
isits in
perten-steroidal anti-inflammatory drugs; OR  odds ratio.
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Non-Steroidals and MI March 17, 2004:985–90n the same week as aspirin, there was no protection from
spirin (OR 1.28; 95% CI: 0.85 to 1.94; p for interaction by
ANSAID use  0.026). This interaction was suggested
or ibuprofen (interaction p  0.057) but not naproxen use
interaction p  0.69) (Fig. 1), suggesting a potential
ifference between the two medications.
As the frequency of NANSAID use increased from
none” to “infrequent” (1 to 3 times/week) to “frequent” (4
imes/week), the ORs for aspirin versus non-aspirin users
ncreased from 0.78 to 0.97 to 2.04 (p  0.006 for linear
rend) (Fig. 2). This interaction by NANSAID frequency
as present for ibuprofen (p  0.018) but not naproxen (p
0.86).
The OR for MI among those using NANSAIDs plus
rophylactic aspirin versus prophylactic aspirin alone was
.92 (95% CI: 0.46 to 1.81). The corresponding OR among
hose using ibuprofen plus prophylactic aspirin versus pro-
hylactic aspirin alone was 1.01 (95% CI: 0.47 to 2.20), and
he OR for other NANSAIDs plus aspirin versus aspirin
lone was 0.61 (95% CI: 0.17 to 2.21). However, those
sing frequent ibuprofen plus aspirin had an OR relative to
spirin-only users of 2.03 (95% CI: 0.60 to 6.84), while the
R for those with infrequent ibuprofen plus aspirin use was
.60 (95% CI: 0.21 to 1.66; p value comparing the two ORs
0.12). The ORs for other NANSAIDs plus aspirin versus
spirin alone were 0.84 (95% CI: 0.18 to 3.93) when the
ANSAIDs were used frequently and 0.35 (95% CI: 0.04
o 3.46) when the NANSAIDs were used infrequently.
ssessment of possible recall and nonparticipation bias.
mong the 182 non-participant controls, 89 (48.9%) re-
igure 1. Odds ratios (boxes) and 95% confidence intervals (bars) for odds
f myocardial infarction among aspirin users versus nonusers of aspirin,
tratified by non-aspirin non-steroidal anti-inflammatory drugs
ANSAIDs). The p value is for test for interaction between aspirin and
ny NANSAID use. Odds ratios are adjusted for age; gender; race;
igarette smoking; insurance; number of doctor visits in the prior year;
amily history of coronary disease; body mass index; activity score; years of
ducation; use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in-
ibitors; and history of diabetes mellitus, hypertension, and hypercholes-
erolemia.orted use of an analgesic. Among 210 participant controls onterviewed during the same months, 119 (56.6%) reported
se of an analgesic for the same indications. Among 129
on-participant cases with medications recorded in the
edical records, 9 (7.0%) had a NANSAID documented
ompared with 66 (9.1%) of 724 participant cases.
In the second substudy, 47 cases had NANSAID use at
ome time before admission (not necessarily in the index
eek) documented in their medical record. Of these 47
ases, 38 (81%) recalled their NANSAID use during their
elephone interview. Of the 10 cases whose records explic-
tly documented NANSAID use in the index week, all 10
100%) recalled their NANSAID use. A total of 37% of the
ANSAIDs recalled were obtained without prescription.
mong 481 cases that denied NANSAID use on telephone
nterview, 472 (98%) cases did not have any NANSAIDs
ocumented in the medical record. In the nine cases that did
ave NANSAIDs documented, the records did not indicate
f the case was actively using the NANSAID at the time of
I.
None of the analyses that adjusted for recall or nonpar-
icipation bias substantially altered the results (Table 3).
ISCUSSION
verall results. This study demonstrates a significant as-
ociation between nonselective NANSAID use and lower
dds of first, nonfatal MI in the absence of concurrent
spirin use. The lower OR for NANSAIDs than for aspirin
as likely due to residual confounding by indication among
spirin users, and should not be interpreted as demonstrat-
ng that NANSAIDs have a greater effect on MI risk than
spirin.
The lower risk of MI among aspirin users, relative to
on-users, was not observed among concomitant NANSAID
sers, particularly those using NANSAIDs with greater
igure 2. Odds ratios (boxes) and 95% confidence intervals (bars) for odds
f myocardial infarction among aspirin users versus nonusers of aspirin,
tratified by frequency of non-aspirin non-steroidal anti-inflammatory
rugs (NANSAIDs) and adjusted for same variables as in Figure 1. The p
alue is for interaction between aspirin and frequency of use of
ANSAIDs. Numbers are less than total because of missing informationn NANSAID frequency in 19 participants.
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March 17, 2004:985–90 Non-Steroidals and MIrequency. This interaction was suggested for ibuprofen
overall p value for interaction of 0.057), particularly with
ncreasing frequency of ibuprofen (p  0.018), but not
aproxen (all p  0.6). The lack of a significant interaction
ith naproxen could be due to limited power and, therefore,
oes not establish a lack of interaction.
It is interesting to note that, in the setting of frequent
ANSAID use, aspirin users had a statistically significantly
ncreased risk of MI relative to non-users of aspirin (Fig 2).
his suggests that perhaps subjects taking frequent
ANSAIDs and using aspirin because of increased risk of
I were not obtaining similar cardioprotection from their
spirin compared with aspirin users who were not using
ANSAIDs or using them infrequently (Fig 2). To attempt
o evaluate this possibility, we directly compared users of
ANSAIDs plus prophylactic aspirin to users of aspirin
lone. We did not find an increased risk overall, but the OR
mong frequent and infrequent users of ibuprofen were 2.03
nd 0.60, respectively, suggesting that there might be an
ffect of regular ibuprofen use. However, the CIs were very
ide. Therefore, our study cannot definitively determine the
ardiac risk from the use of NANSAIDs, and ibuprofen in
articular, among patients using aspirin. However, a recent
tudy of patients with known cardiovascular disease, a
opulation different from ours, has demonstrated a higher
ate of overall mortality and cardiovascular death (not MI
er se) among users of ibuprofen plus aspirin relative to
spirin alone (15).
rior studies of nonselective NANSAIDs and MI.
everal prior studies, including a randomized trial (16), have
uggested that NANSAIDs themselves might protect
gainst MI (16–18), but five nonexperimental studies have
roduced inconsistent results (3–7). Our study provides a
ossible explanation for these discrepant findings; the re-
ults of these prior studies may be explained by their use of
lectronic prescription records to estimate NANSAID use.
s a result, they could not identify non-prescription
ANSAID use nor estimate the effect of NANSAIDs
eparately in non-aspirin users. With respect to the former,
large proportion of NANSAID use is likely to be
Table 3. Assessment of Effects of Recall and N
Primary study results (NANSAIDs vs. no NANSAI
Adjustment for recall bias
Only those with all medication containers availabl
during interview
Only those interviewed within 90 days of index da
Adjustment for nonparticipation
Using results from nonparticipation studies
Adjustment for both recall and nonparticipation bias
NANSAIDs vs. acetaminophen
*Adjusted for same variables as in Table 2.
CI  confidence interval; NANSAIDs  non-aspirin noon-prescription (19) (80% of all NANSAID use amongur controls, and even 47% of NANSAID among the
edicaid population). These non-prescription NANSAID
sers would have been characterized as “unexposed” in these
rior database studies. The lack of data on non-prescription
spirin use (20) also prohibited the analysis of non-aspirin
sers separately from aspirin users. When, in our study, we
ompare prescription NANSAID users to all other partic-
pants (i.e., including non-prescription NANSAID users
long with non-users of NANSAIDs) and do not exclude
spirin users, our OR for NANSAIDs and MI is 1.0. This
ias would be more pronounced for ibuprofen than
aproxen, because ibuprofen is a more commonly used
ver-the-counter drug (8) and because of the potential
nteraction of ibuprofen with aspirin. Thus, the same
nalysis above yields an OR of 1.1 for ibuprofen and 0.6 for
aproxen. Therefore, it is possible that the results of the
rior studies, including the differences observed between
aproxen and ibuprofen, are due to these biases. Inability to
ontrol for important confounders in administrative data-
ases (e.g., body mass index, physical activity) may also
ccount for some of the differences.
Our results also suggest that at least some of the differ-
nce in MI rates between naproxen and rofecoxib in the
bsence of aspirin use noted in the Vioxx Gastrointestinal
utcomes Research study (9) could be due to a protective
ffect of naproxen. However, different results comparing
elecoxib with other NANSAIDs (ibuprofen and diclofe-
ac) (21) and recent data on rofecoxib (22) raise the
ossibility that there could be differences in cardiovascular
isk among COX-2 inhibitors (23).
otential limitations. Several potential limitations should
e considered in interpreting our results. Although our
nalysis comparing NANSAIDs with acetaminophen sug-
ests that there was some recall bias, this bias was not
ufficient to create the study findings. Because acetamino-
hen is an over-the-counter analgesic, like many of the
ANSAIDs in this study, a comparison of NANSAIDs
ith acetaminophen should not be biased by differential
ecall. In fact, this comparison should overestimate the effect
f recall bias because we did not use memory aids to improve
ecall for acetaminophen (12,13). In addition, other adjust-
articipation Bias
No Aspirin Use
Adjusted OR*
(95% CI)
Aspirin Use
Adjusted OR*
(95% CI)
0.53 (0.42–0.67) 0.83 (0.58–1.17)
0.53 (0.37–0.76) 0.72 (0.41–1.25)
0.60 (0.45–0.79) 0.78 (0.52–1.17)
0.59 (0.42–0.81) 0.92 (0.61–1.37)
0.66 (0.47–0.92) 1.02 (0.60–1.73)
oidal anti-inflammatory drugs; OR  odds ratio.on-P
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Non-Steroidals and MI March 17, 2004:985–90ent for recall did not alter the results (Table 3). Finally,
djusting for the 81% recall of NANSAID use among cases
n our chart substudy, our OR for NANSAIDs among
on-aspirin users would be 0.56 and among aspirin users
ould be 0.89. Second, selection bias was minimized in this
tudy by randomly selecting controls from the same source
opulation as the cases. Nonparticipation bias, a type of
election bias, is possible, but adjustment for estimates of
onparticipation did not alter the results. Third, uncon-
rolled confounding is always possible, even with our exten-
ive adjustment for almost all known cardiac risk factors.
ourth, because we included only nonfatal MIs, a false
ssociation could occur if NANSAIDs had no effect on, or
ncreased the risk of, fatal MI, particularly sudden death.
owever, clinical trial data suggest that this is very unlikely
24), consistent with the effects of NANSAIDs after ex-
luding fatal coronary heart disease events in a prior study
7). Even if NANSAIDs had no effect on the estimated 30%
f MIs that are fatal (25), our results would still be
ignificant (OR of 0.68). Of course, further study is needed
o determine the effects of NANSAIDs specifically on fatal
I.
onclusions. Our results suggest that nonselective
ANSAIDs may, themselves, reduce the risk of MI. If this
nintended benefit of MI protection is confirmed with
dditional studies (and, optimally, randomized trials), the
isk-benefit ratio of nonselective NANSAIDs will have to
e reassessed. However, the cardioprotective effects of
spirin are well established, and nonselective NANSAIDs
hould not be considered alternatives to aspirin for preven-
ion. Although our study cannot determine definitively if
dding ibuprofen to aspirin use increases the risk of MI
elative to aspirin use alone, recent data suggest that this
ould be the case (15). Further study is needed to assess the
linical relevance of the pharmacological interaction of
buprofen with aspirin.
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